Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

C4 Therapeutics (CCCC) Total Liabilities (2019 - 2025)

Historic Total Liabilities for C4 Therapeutics (CCCC) over the last 7 years, with Q3 2025 value amounting to $111.1 million.

  • C4 Therapeutics' Total Liabilities fell 1673.41% to $111.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $111.1 million, marking a year-over-year decrease of 1673.41%. This contributed to the annual value of $133.6 million for FY2024, which is 251.58% up from last year.
  • C4 Therapeutics' Total Liabilities amounted to $111.1 million in Q3 2025, which was down 1673.41% from $122.5 million recorded in Q2 2025.
  • In the past 5 years, C4 Therapeutics' Total Liabilities ranged from a high of $151.0 million in Q1 2022 and a low of $109.1 million during Q3 2021
  • For the 5-year period, C4 Therapeutics' Total Liabilities averaged around $129.1 million, with its median value being $133.4 million (2024).
  • As far as peak fluctuations go, C4 Therapeutics' Total Liabilities skyrocketed by 3685.7% in 2022, and later crashed by 1833.8% in 2023.
  • C4 Therapeutics' Total Liabilities (Quarter) stood at $117.2 million in 2021, then increased by 20.87% to $141.6 million in 2022, then fell by 7.96% to $130.3 million in 2023, then grew by 2.52% to $133.6 million in 2024, then fell by 16.87% to $111.1 million in 2025.
  • Its Total Liabilities was $111.1 million in Q3 2025, compared to $122.5 million in Q2 2025 and $124.4 million in Q1 2025.